STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 3] Revolution Medicines, Inc. Initial Statement of Beneficial Ownership

Anthony Mancini of Revolution Medicines (RVMD) details stock options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Anthony Mancini filed an initial statement of beneficial ownership, detailing his existing equity position rather than reporting new trades. He directly holds 54,400 shares of Common Stock as Restricted Stock Units.

He also holds stock options over 149,800 shares of Common Stock at an exercise price of $33.62 per share, expiring on March 31, 2035. Twenty-five percent of these option shares vest on the first anniversary of the April 1, 2025 vesting commencement date, with the remainder vesting monthly over four years.

A separate stock option covers 26,200 shares of Common Stock at an exercise price of $102.02 per share, expiring on February 28, 2036. One forty-eighth of these shares vests on each monthly anniversary of the March 1, 2026 vesting commencement date, so they become fully vested after four years of continued service.

Positive

  • None.

Negative

  • None.
Insider Mancini Anthony
Role See Remarks
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 176,000 shares (Direct); Common Stock — 54,400 shares (Direct)
Footnotes (3)
  1. F1. Includes 54,400 Restricted Stock Units.
  2. F2. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  3. F3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does Anthony Mancini’s Form 3 for Revolution Medicines (RVMD) show?
The Form 3 shows Anthony Mancini’s existing equity holdings in Revolution Medicines, including stock options and restricted stock units, at the time he became a reporting insider, rather than reporting any new stock purchases or sales.

How many restricted stock units does Anthony Mancini hold in RVMD?
Anthony Mancini holds 54,400 Restricted Stock Units of Revolution Medicines common stock. These RSUs represent shares that typically settle into stock over time, subject to service conditions and the company’s standard vesting and settlement practices.

What stock options does Anthony Mancini report for Revolution Medicines (RVMD)?
He reports two stock option awards: one over 149,800 shares at $33.62 expiring March 31, 2035, and another over 26,200 shares at $102.02 expiring February 28, 2036, both giving the right to buy common stock.

How do the 149,800-share RVMD stock options held by Mancini vest?
For the 149,800-share option, 25% of the shares vest on the first anniversary of the April 1, 2025 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years of continued service.

What is the vesting schedule for Mancini’s 26,200-share RVMD stock option?
For the 26,200-share option, one forty-eighth of the shares vests on each monthly anniversary of the March 1, 2026 vesting commencement date, so all shares become fully vested and exercisable after four years of continuous service.

Does Mancini’s RVMD Form 3 indicate any recent stock trades?
The Form 3 reflects holdings as of becoming an insider and shows no buy or sell transactions. It lists stock options and restricted stock units, indicating his starting ownership position rather than new market activity in Revolution Medicines shares.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Mancini Anthony
(Last)(First)(Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/20/2026		3. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock54,400(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2)03/31/2035Common Stock149,800$33.62D
Stock Option (Right to Buy) (3)02/28/2036Common Stock26,200$102.02D
Explanation of Responses:
1. Includes 54,400 Restricted Stock Units.
2. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Remarks:
Chief Global Commercialization Officer Exhibit 24 - Power of Attorney
/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini03/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR